This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Deal: Roche Cuts Deal With Inovio for Cancer, Hep B Therapies

NEW YORK The Deal -- Blue Bell, Pa.-based Inovio Pharmaceuticals (INO), has out-licensed two preclinical DNA immunotherapies, for prostate cancer and hepatitis B, plus a technology platform to Swiss drugs giant Roche Holdings.

Roche will make a $10 million up-front payment to Inovio with development and commercial milestones of up to $412.5 million for an exclusive worldwide license to the drug candidates and exclusive use of Inovio's Cellectra electroporation technology for delivery of the vaccines. Roche also has an option to license additional vaccines for cancers.

INO-5150 is a dual-antigen synthetic DNA vaccine that targets prostate-specific membrane antigen and prostate-specific antigen. Monkeys vaccinated with the compound generated "strong and robust T-cell immune response," according to Inovio. Those responses were the highest generated by a PSA-based immunotherapy in animal studies, the company said.

"IN0-5150 will allow promising combination opportunities with the Roche portfolio, particularly with our emerging cancer immunotherapeutic molecules," Hy Levitsky, Roche head of cancer immunology experimental medicine, said in a statement.

Roche has no therapies for hepatitis B in development, according to its official pipeline.

Another experimental vaccine in the deal, INO-1800, generated strong T-cell and antibody responses that led to the elimination of targeted liver cells in mice. "Those results indicate this DNA vaccine's potential to treat hepatitis B infection and prevent further development of the infection into liver cancer in humans," Inovio said.

"Collaborating with the world's pre-eminent oncology development partner allows us to rapidly advance two of our promising near-clinical stage immunotherapy products from our product pipeline as we continue our Phase 2 lead product, VGX-3100," J. Joseph Kim, Inovio president and CEO, said in a statement.

Roche presented promising data on its cancer immunotherapy anti-PDL1 antibody RG7446 at the American Society of Clinical Oncology this year. The compound is designed to make cancer cells more vulnerable to the body's immune system.

Roche's biologics arm, Genentech (DNA), is working on a Phase 1 prostate cancer therapy, RG7450, which it licensed from Seattle Genetics (SGEN). It's an antibody-drug conjugate made up of a humanized monoclonal antibody directed against STEAP-1, a membrane protein overexpressed in cancer.

Inovio also is working on is own VGX-3100, a therapeutic vaccine for human papilloma virus that the company says has generated "best-in-class T-cell responses in a Phase 1 study."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs